Xenograft models of ACC-I were responsive to PRMT5 inhibition with a block of tumour growth (85); AL101 determined tumour regression in NOTCH activated ACC-I models and further synergic activity was observed when used in combination with BCL2 inhibitor or palbociclib (86). Here, PRMT5 is linked to neoplasm.